Addex Therapeutics Ltd. (ADXN)
3.18
+0.08
(+2.58%)
USD |
NASDAQ |
Oct 06, 16:00
2.97
-0.21
(-6.60%)
After-Hours: 20:00
Addex Therapeutics Enterprise Value : 2.436M for Oct. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 05, 2026 | 2.436M |
| October 02, 2026 | 2.404M |
| October 01, 2026 | 2.309M |
| September 30, 2026 | 2.075M |
| September 29, 2026 | 2.277M |
| September 28, 2026 | 2.128M |
| September 25, 2026 | 3.020M |
| September 24, 2026 | 2.819M |
| September 23, 2026 | 2.808M |
| September 22, 2026 | 2.861M |
| September 21, 2026 | 2.893M |
| September 18, 2026 | 2.755M |
| September 17, 2026 | 2.712M |
| September 16, 2026 | 2.712M |
| September 15, 2026 | 2.606M |
| September 14, 2026 | 2.840M |
| September 11, 2026 | 2.850M |
| September 10, 2026 | 2.744M |
| September 09, 2026 | 2.978M |
| September 08, 2026 | 3.074M |
| September 04, 2026 | 3.020M |
| September 03, 2026 | 3.084M |
| September 02, 2026 | 2.882M |
| September 01, 2026 | 3.020M |
| August 31, 2026 | 3.307M |
| Date | Value |
|---|---|
| August 28, 2026 | 3.222M |
| August 27, 2026 | 3.233M |
| August 26, 2026 | 3.636M |
| August 25, 2026 | 3.286M |
| August 24, 2026 | 3.445M |
| August 21, 2026 | 4.390M |
| August 20, 2026 | 3.997M |
| August 19, 2026 | 5.197M |
| August 18, 2026 | 5.197M |
| August 17, 2026 | 5.197M |
| August 14, 2026 | 5.462M |
| August 13, 2026 | 5.462M |
| August 12, 2026 | 5.462M |
| August 11, 2026 | 5.462M |
| August 10, 2026 | 5.462M |
| August 07, 2026 | 5.303M |
| August 06, 2026 | 5.303M |
| August 05, 2026 | 5.186M |
| August 04, 2026 | 5.186M |
| August 03, 2026 | 4.666M |
| July 31, 2026 | 4.666M |
| July 30, 2026 | 5.086M |
| July 29, 2026 | 5.394M |
| July 28, 2026 | 5.394M |
| July 27, 2026 | 5.394M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novartis AG | 299.71B |
| Roche Holding AG | -- |
| Oculis Holding AG | 248.53M |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.207M |
| Revenue (Quarterly) | 0.0126M |
| Total Expenses (Quarterly) | 2.22M |
| EPS Diluted (Quarterly) | -2.160 |
| Gross Profit Margin (Quarterly) | -153.2% |
| Profit Margin (Quarterly) | -17.52K% |
| Earnings Yield | -277.1% |
| Normalized Earnings Yield | -277.04 |